Every year on 18 May, World AIDS Vaccine Day invites the global health community to pause. Not to celebrate prematurely, but to confront a defining question that has shaped more than four decades of global health action: are we truly on a path to end AIDS, or have we learned to manage it indefinitely?
In 2026, that question carries new weight. Not because the epidemic has disappeared, it has not, but because science, partnership, and lived experience are converging in ways that were unimaginable a decade ago. The momentum we are witnessing today is not rooted in optimism alone. It is grounded in evidence, hard-won collaboration, and the voices of communities who have carried the burden of this epidemic for far too long.
Where the World Stands, and Why Urgency Still Matters
HIV remains one of the most persistent global health challenges of our time. More than 40 million people worldwide are living with HIV. Each year, approximately 1.3 million people newly acquire the virus, and hundreds of thousands continue to die from AIDS-related illnesses. These outcomes persist not because solutions do not exist, but because access to them remains unequal, unstable, and politically fragile.
There has been real progress. Antiretroviral therapy has transformed HIV from a fatal diagnosis into a manageable chronic condition for millions. Prevention tools are more effective, more diverse, and increasingly long-acting. Yet these gains are not evenly shared. This is why global targets such as 95-95-95 are not abstract technical benchmarks. They are public health promises. Every percentage point represents lives reached, or lives overlooked.
Who Remains Most Affected, and Why Vulnerability Is Structural
Across regions and income settings, the same pattern endures: HIV risk follows inequality as closely as it follows biology. Women and girls, particularly adolescent girls and young women, continue to shoulder a disproportionate share of new infections. In many contexts, vulnerability is shaped by unequal power relations, gender-based violence, limited access to education, economic dependence, stigma, and restrictive social norms.
Vulnerability is not theoretical. It is lived:
- By individuals navigating health systems that feel unsafe or exclusionary
- By communities criminalised for who they are or how they survive
- By populations erased by law, policy, or silence
- By people forced to choose between care and daily survival
Effective HIV responses acknowledge this reality. The strongest strategies place people and communities at the centre, confronting stigma, discrimination, and structural barriers alongside biomedical innovation.
What Has Already Changed, and Why It Deserves Recognition
The global HIV response has rewritten what survival looks like. Millions now live long, productive lives with sustained viral suppression, benefiting not only themselves but public health as a whole. Prevention has evolved as well. The scale-up of oral PrEP proved that prevention choice can be integrated into real-world health systems when dignity, privacy, informed consent, and non-discrimination are treated as foundational principles, not optional add-ons.
Perhaps most transformative has been the shift toward combination prevention: layered strategies that integrate testing, treatment, biomedical tools, social support, and protection from violence. This reflects a hard-earned truth from public health practice: prevention works when it aligns with how people actually live.
A Breakthrough That Reframed What Is Possible
Recent scientific advances have reshaped global thinking about HIV prevention. Long-acting injectable prevention tools, administered just twice a year, have demonstrated extraordinarily high effectiveness in clinical trials. One of the most significant of these advances is lenacapavir, a long-acting capsid inhibitor that has demonstrated remarkable efficacy as twice-yearly pre-exposure prophylaxis in clinical trials. While not a vaccine, lenacapavir represents a paradigm shift in what durable HIV prevention can look like when scientific innovation prioritises adherence, discretion, and feasibility. Its success underscores a critical lesson for the field: prevention tools are most powerful when they are designed around people’s lived realities, a principle that is equally essential for future vaccine development.
Conclusion: The Choice Before Us
World AIDS Vaccine Day reminds us that history does not turn on discoveries alone, but on decisions. We now stand at a rare intersection where science has opened new possibilities, where communities have shown what works, and where the path forward is finally visible. Ending AIDS is no longer a question of whether it is possible, but of whether we will act with the urgency, equity, and courage this moment demands. The breakthrough is within reach. What determines its legacy is who we choose to reach, protect, and prioritise now.
Written by ISID Emerging Leader, Nelisiwe Mhlabane